Novel Anti-HLA-Pan-DP CAR-T cells for Targeted Cancer Immunotherapy

Technology Description

Introducing a transformative innovation in immunotherapy for hematological malignancies, including B-cell lymphomas, multiple myeloma, and blastic plasmacytoid dendritic cell neoplasm. Our cutting-edge CAR T-cell therapy targets HLA-DP, a novel and consistently expressed molecule across various stages of B-cell maturation, addressing the challenges of antigen downregulation that often lead to relapse in CD19- and BCMA-targeted therapies. Featuring a proprietary CAR construct with a single-chain variable fragment (scFv) that binds selectively to HLA-DP, this therapy activates T-cell cytotoxic functions to eliminate cancer cells. Preclinical studies demonstrate potent and specific killing of HLA-DP-expressing cancer cells without off-target effects, along with robust efficacy in vivo in lymphoma and multiple myeloma models. Designed to bridge patients to hematopoietic stem cell transplantation, this innovative CAR T-cell therapy offers hope for improved long-term outcomes in therapy-resistant hematological malignancies.

Stage of Development

Pre-clinical proof of concept. 

Related Materials